1. Truncation of WT1 results in downregulation of cyclin G1 and IGFBP-4 expression
- Author
-
Sheila Christie, Colin G. Miles, Martin L. Hooper, Kate J. Wagner, Charles E. Patek, and Anthony J. Brookes
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Cyclin G1 ,Biophysics ,Down-Regulation ,Antineoplastic Agents ,Tretinoin ,Biology ,urologic and male genital diseases ,Biochemistry ,Cell Line ,Cyclin G ,Cyclin D1 ,Complementary DNA ,Cyclins ,Gene expression ,Humans ,WT1 Proteins ,Gene ,Molecular Biology ,Cyclin ,Oligonucleotide Array Sequence Analysis ,Zinc finger transcription factor ,urogenital system ,Gene targeting ,Cell Biology ,Molecular biology ,female genital diseases and pregnancy complications ,Insulin-Like Growth Factor Binding Protein 4 ,Gene Targeting ,Cyclin A2 - Abstract
Mutations in the WT1 gene are found in a subset of Wilms' tumours and in certain other disorders such as Denys-Drash syndrome. The WT1 gene product is a zinc finger transcription factor for which many target genes have been suggested. Here we utilise gene targeting to generate cells containing only truncated forms of WT1, in which the DNA-binding region is disrupted. Examination of gene expression in these cells using cDNA macroarrays suggests two novel WT1 transcriptional targets, cyclin G1 (Ccng1), and insulin-like growth factor binding protein 4 (Igfbp4).
- Published
- 2001